Apellis Pharmaceuticals
Financial ratios & Valuation

Forward Multiples (2025 – 2028)

2025202620272028
Price/Earnings ratio
27.408.336.014.93
Price/Sales ratio
2.171.561.471.32
Earnings per Share (EPS)
$0.97$3.19$4.42$5.39

Historical Multiples (2014 – 2023)

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 TTM Median
Valuation Ratios
Price/Earnings ratio
-23.52-5.45-9.35-5.90-5.62-6.15-12.46-5.34-8.41-13.43-13.32-6.15
Price/Sales ratio
N/AN/AN/AN/AN/AN/A17.1559.9672.7517.91115.24N/A
Price/Book Value ratio
19.197.2510.662.024.4555.6621.0120.0932.3036.5251.164.45
Price/Cash Flow ratio
-25.51-13.46-9.76-6.45-5.46-9.02-26.78-7.08-10.68-11.94-16.91-9.02
Price/Free Cash Flow ratio
-25.46-13.46-9.76-6.45-5.46-8.95-25.91-7.07-10.64-11.92-16.86-8.95
Price/Earnings Growth ratio
-0.13-0.010.22-0.040.15-0.051.59-0.050.270.48-0.41-0.05
Dividend Yield
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Profitability Indicator Ratios
Gross Profit Margin
N/AN/AN/AN/AN/AN/A90.00%92.18%92.52%85.24%92.52%N/A
Operating Profit Margin
N/AN/AN/AN/AN/AN/A-85.27%-805.66%-788.38%-130.39%-788.38%N/A
Pretax Profit Margin
N/AN/AN/AN/AN/AN/A-136.85%-1120.74%-863.81%-132.75%-863.81%N/A
Net Profit Margin
N/AN/AN/AN/AN/AN/A-137.59%-1121.27%-864.69%-133.29%-864.69%N/A
Effective Tax Rate
3.94%57.04%100.58%-0.49%0.41%-1.67%-0.53%-0.04%-0.10%-0.40%-0.10%-1.67%
Return on Assets
-75.41%-121.84%-98.87%-28.00%-62.64%-79.59%-35.90%-84.64%-85.78%-67.02%-85.78%-79.59%
Return On Equity
-81.57%-132.99%-113.99%-34.24%-79.20%-905.10%-168.59%-375.69%-383.91%-271.75%-204.77%-204.77%
Return on Capital Employed
-85.40%-133.15%-114.65%-28.91%-68.58%-89.03%-25.68%-71.51%-100.33%-95.56%-100.33%-89.03%
Liquidity Ratios
Current Ratio
N/AN/AN/A27.7711.895.677.14N/AN/AN/A4.295.67
Quick Ratio
13.0411.887.5227.7711.895.677.146.123.782.503.335.67
Cash ratio
12.5911.256.8326.7910.355.354.404.853.291.413.295.35
Days of Sales Outstanding
N/AN/AN/AN/AN/AN/A36.4055.4037.39189.9937.39N/A
Days of Inventory outstanding
N/AN/AN/AN/AN/AN/A0.001.14K5.55K913.045.55KN/A
Operating Cycle
N/AN/AN/AN/AN/AN/A36.401.19K5.58K1.10K5.56KN/A
Days of Payables Outstanding
N/AN/AN/A26.3329.2510.59123.511.18K2.41K234.032.41K29.25
Cash Conversion Cycle
N/AN/AN/AN/AN/AN/A-87.1111.673.17K869.00-1.01KN/A
Debt Ratios
Debt Ratio
N/AN/AN/A0.140.130.370.370.210.120.110.770.13
Debt Equity Ratio
N/AN/AN/A0.170.164.241.750.950.540.473.470.16
Long-term Debt to Capitalization
N/AN/AN/A0.150.130.800.630.480.350.320.380.13
Total Debt to Capitalization
N/AN/AN/A0.150.140.800.630.480.350.320.390.14
Interest Coverage Ratio
N/AN/AN/AN/A-50.90-54.50-7.13N/AN/AN/A-18.22-50.90
Cash Flow to Debt Ratio
N/AN/AN/A-1.76-4.85-1.45-0.44-2.97-5.53-6.39-4.55-4.85
Company Equity Multiplier
1.081.091.151.221.2611.374.694.434.474.054.471.26
Cash Flow Ratios
Operating Cash Flow / Sales Ratio
N/AN/AN/AN/AN/AN/A-0.64-8.46-6.81-1.49-6.81N/A
Free Cash Flow / Operating Cash Flow Ratio
1.0011111.001.031.001.001.001.001
Cash Flow Coverage Ratio
N/AN/AN/A-1.76-4.85-1.45-0.44-2.97-5.53-6.39-4.55-4.85
Short Term Coverage Ratio
N/AN/AN/AN/A-78.74-80.91N/AN/AN/AN/A-91.33-80.91
Dividend Payout Ratio
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A